Approximately a quarter of individuals with primary sclerosing cholangitis experience moderate-severe pruritus.

Adjuvant systemic therapy was associated with improved rates of overall survival among patients who underwent surgical resection for MM.

Amlitelimab is effective at improving moderate to severe AD across all body regions, including the difficult-to-treat head and neck region.

The National Institutes of Health announced that it will end its funding of research that uses human fetal tissue.